Back to search results

Microneedling with CBD and Hempseed Oil for Acne Vulgaris

This study is looking at how safe and effective microneedling with a combination of Cannabidiol (CBD) and organic hemp seed oil is for treating moderate to severe acne (Acne Vulgaris). You might be able to join if you are 22 years or older and have moderate, severe, or very severe acne. The study aims to see if this treatment can reduce the appearance of facial acne. Researchers will measure how well the treatment works over about 70 days. The current recruitment status is unclear, and the study plans to enroll 20 participants.

Study design
This is an open-label study, meaning both you and the researchers will know what treatment you are receiving. It is a single-center study, planning to enroll 20 participants.
What's involved
Not specified in the trial record.
Compensation
Not stated in the trial record.
Follow-up
The primary effectiveness of the treatment will be measured through study completion, which is approximately 70 days.

AI-generated from the public study record. Only the study team can confirm whether you're eligible — confirm details with them before making decisions.

NCT06362889

Evaluating Microneedling With CBD and Hempseed Oil for Acne Vulgaris Safety and Efficacy

Not Yet Recruiting
PHASE1Ages 22+InterventionalTreatment
Rejuva Medical Aesthetics
~20 participants
Updated 2024-08-23 on ClinicalTrials.gov
What's tested:Microneedling with CBD

At a glance

Recruiting sites
0 of 1 listed site is recruiting right now
RecruitingSuspended, closed, or not yet open
What they're measuring
Primary efficacy endpoints
Measured over through study completion, approximately 70 days

Conditions

Acne Vulgaris (Disorder)

Explore related trials

Acne

Where it's being run

1 sites across 1 states
California1

Study leadership

  • Kian Karimi, MD · PRINCIPAL_INVESTIGATOR · Rejuva Medical Aesthetics

Who to contact

LaRyel Waldon, BS
[email protected]
4246442400
Email the study team

Opens a ready-to-send draft in your own email app — review before sending.

Do you actually qualify for this trial?

Add a private profile and we'll compare every criterion below against your situation — and tell you which ones are met, uncertain, or excluding.

Check eligibility for this trial ~2 min · HIPAA-protected · delete anytime
Eligibility criteria

Inclusion

Male or non-pregnant, non-lactating female, 22 years of age or older. Females of childbearing potential must agree to the use of a reliable method of contraception throughout the study.
Have a Global Acne Severity Scale Score of 3 (Moderate), 4 (Severe), or 5 (Very severe).
Have no plans to begin a new skincare routine or medical treatment program (Accutane) through the course of the study.
Willing to abstain from any aesthetic or surgical procedure in the treatment area for the duration of the study.

Exclusion

Significant history or current evidence of any uncontrolled chronic or serious disease or medical condition that would, in the judgment of the investigator, would put the subject at undue risk or compromise the study assessments.
Employees of the Investigator or research center or their immediate family members.
Inability to understand the requirements of the study and the relative information and are unable or not willing to comply with the study protocol.
The use of Accutane (Isotretinoin) within 6-months.
The use of topical or oral therapies that include benzoyl peroxide, azelaic acid, salicylic acid, and hydroquinone 30 days prior to study entry.
Exposure to any other investigational drug/device within 30 days prior to study entry.
Sunburned at time of anticipated treatment. Subject must also be willing to avoid significant sun exposure throughout participation
Recent facial plastic surgery, aesthetic treatment, or dermatological treatment at treatment sites that would interfere with ability to receive microneedling.
Facial hair that would interfere with the visualization of treatment sites.
Subject with abnormal vision assessments.
Subject is known to be noncompliant or is unlikely to comply with the requirements of the study protocol (e.g. due to alcoholism, drug dependency, mental incapacity) in the opinion of the investigator.

What this trial measures

  • Primary efficacy endpointsthrough study completion, approximately 70 days

    Reduction in the Global Acne Severity Scale (GAS) grade by Primary Investigator Reduction in the GAS grade by the Subject